EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma

Monica Majumder iD, Cherie Chiang, Grace Kong, Michael Michael, Nirupa Sachithanandan, Emma Boehm

Clinical Endocrinology · 2025

DOI: 10.1111/cen.15235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Monica Majumder und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Diabetes Department, St Vincent's Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms, Gastrointestinal Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Managing gastrointestinal symptoms in patients with phaeochromocytoma and paraganglioma (PPGL) is challenging due to the risk of catecholaminergic crisis with many commonly prescribed medications, especially in functional tumours. We reviewed gastrointestinal symptom management and outcomes in PPGL patients at our centre and developed recommendations based on a literature review and our experience. Design, Patients, Measurement A single‐centre retrospective analysis of the management of gastrointestinal symptoms in patients with PPGL between 2019 and 2024 was completed. A literature review of gastrointestinal manifestations in PPGL was undertaken.

Results

Twenty‐four individuals with PPGL admitted for radionuclide therapy, chemotherapy, surgery or other medical illness were included. Eighteen (75%) had metastatic disease. Fifty administration events of antiemetics for nausea or vomiting occurred. Two patients had acute colonic pseudo‐obstruction. Dopamine antagonists (metoclopramide) and corticosteroids (dexamethasone) were administered to 10 and 9 patients, respectively, the majority of whom were alpha‐blocked ( n = 7) or had a dopaminergic/biochemically silent phenotype ( n = 10). A patient with noradrenergic PPGL experienced a hypertensive episode following high‐dose dexamethasone. No patients with biochemically negative/dopaminergic phenotypes or on alpha blockade experienced an antiemetic‐related adverse event. Published evidence of dopamine antagonists and corticosteroids precipitating catecholaminergic crisis was mostly limited to case reports. While low‐risk antiemetics (serotonin, histamine or neurokinin antagonists) are preferable, we found higher‐risk antiemetics (dexamethasone and metoclopramide) can be cautiously administered in patients with a biochemically negative/dopaminergic phenotype or in those on adequate alpha blockade. Limited case reports demonstrated anti‐cholinergic agents were beneficial for the management of acute colonic pseudo‐obstruction.

Conclusions

Optimal management of gastrointestinal symptoms in PPGL should consider disease characteristics such as primary location, secretory profile, alpha blockade and medication profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PheochromocytomaParagangliomaAdrenal Gland NeoplasmsGastrointestinal DiseasesHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAgedAntiemeticsVomitingDexamethasoneDopamine AntagonistsMetoclopramide

Stichwörter der Autor:innen

acute colonic pseudo‐obstructionantiemeticscatecholamine crisesconstipationgastrointestinal symptomshypertensive crisisobstipationparagangliomaphaeochromocytoma

Substanzen

AntiemeticsDexamethasoneDopamine AntagonistsMetoclopramide

Autor:innen und Institutionen

  • Endocrinology and Diabetes Department, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, The University of Melbourne, Fitzroy, Victoria, Australia.
  • Department of Internal Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

ORCID-Profile: Monica Majumder

Zitieren

APA

Majumder, M., Chiang, C., Kong, G., Michael, M., Sachithanandan, N., & Boehm, E. (2025). Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma. Clinical Endocrinology. https://doi.org/10.1111/cen.15235

Vancouver

Majumder M, Chiang C, Kong G, Michael M, Sachithanandan N, Boehm E. Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma. Clinical Endocrinology. 2025. doi:10.1111/cen.15235

BibTeX
@article{Majumder2025,
  author = {Majumder, Monica and Chiang, Cherie and Kong, Grace and Michael, Michael and Sachithanandan, Nirupa and Boehm, Emma},
  title = {Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma},
  journal = {Clinical Endocrinology},
  year = {2025},
  doi = {10.1111/cen.15235}
}
Kostenlos starten →